株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

精密医療 (プレシジョンメディシン) の世界市場 - 分析・予測 (2018-2028年):応用科学・精密診断・デジタルヘルス & IT・精密治療

Global Precision Medicine Market: Focus on Precision Medicine Ecosystem, Applications, 13 Countries Mapping and Competitive Landscape - Analysis and Forecast 2018-2028

発行 BIS Research Inc. 商品コード 781860
出版日 ページ情報 英文 544 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
精密医療 (プレシジョンメディシン) の世界市場 - 分析・予測 (2018-2028年):応用科学・精密診断・デジタルヘルス & IT・精密治療 Global Precision Medicine Market: Focus on Precision Medicine Ecosystem, Applications, 13 Countries Mapping and Competitive Landscape - Analysis and Forecast 2018-2028
出版日: 2019年01月29日 ページ情報: 英文 544 Pages
概要

世界の精密医療 (プレシジョンメディシン) 市場は、2018年までに2,167億5,000万米ドルへ達すると予測されています。

当レポートでは、世界の精密医療 (プレシジョンメディシン) 市場を調査し、市場の概要、市場成長の促進要因・課題・機会、各セグメント別の市場規模、地域市場の分析、および主要企業のプロファイルなどを提供しています。

Figure 5.37 Global Precision Medicine Market

エグゼクティブサマリー

第1章 市場概要

  • イントロダクション
  • 精密医療:患者中心医療の発生におけるフロンティア
  • 精密医療:画一的な理論から個人に合わせた治療へのリモデリング
  • イニシアチブ・プログラム
  • 市場規模計算の前提条件・制限事項
  • 精密医療:イネーブリング技術

第2章 市場力学

  • 影響分析
  • 市場成長推進因子
  • 市場成長抑制因子
  • 市場機会

第3章 競合考察

  • 主な戦略・発展
  • 市場シェア分析
  • 産業の魅力
  • サプライチェーン分析

第4章 産業考察

  • 特許分析
  • 法的要件・規制
  • パイプライン分析

第5章 世界の精密医療市場:エコシステム別

  • 概要
  • 応用科学
  • 精密診断
  • デジタルヘルスおよび情報技術 (IT)
  • 精密治療

第6章 世界の精密医療市場:用途別

  • 概要
  • 感染症
  • 神経学/リハビリテーション医学
  • 心血管
  • ライフスタイル・内分泌学
  • 消化器
  • その他の用途

第7章 世界の精密医療市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋 (APAC)
  • ラテンアメリカ
  • その他 (ROW)

第8章 企業プロファイル

第9章 調査範囲・調査手法

図表

List of Tables

  • Table 1: Comparison of China and the U.S. Healthcare Statistics
  • Table 1.1: Initiatives and Programs
  • Table 2.1: Impact Analysis
  • Table 2.2: Percentage of Total Regional Aged Population (65 years & above: 2015 & 2030)
  • Table 2.3: Cancer Incidence by WHO Region, 2012 (Thousands)
  • Table 2.4: Cancer Incidence Type in Thousand, 2012 (WHO)
  • Table 2.5: Policy and Guidance Documents from the U.S. FDA
  • Table 4.1: Pipeline Analysis
  • Table 4.2: Precision Medicine Drugs Pipeline Analysis
  • Table 5.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling
  • Table 5.2: Key Approved Therapeutics with FDA Mandated Companion Diagnostics Tests
  • Table 5.3: List of FDA Approved Companion Diagnostics
  • Table 5.4: Commercially Available Primary and Secondary Analysis Tools Providers
  • Table 6.1: Cancer Precision Medicine Drugs and Indications
  • Table 6.2: Recent Key Developments
  • Table 6.3: Infectious Diseases Precision Medicine Drugs and Indications
  • Table 6.4: Neurology Precision Medicine Drugs and Indications
  • Table 6.5: Cardiovascular Precision Medicine Drugs/Tests/ and Indications
  • Table 6.6: Endocrinology Precision Medicine Drugs and Indications
  • Table 6.7: Gastroenterology Precision Medicine Drugs and Indications
  • Table 6.8: Precision Drugs for Other Applications
  • Table 7.1: Funding scenario in Universities

List of Figures

  • Figure 1: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure
  • Figure 2: Precision Medicine - a Multi-Faceted Approach to Patient Care
  • Figure 3: Chronic Conditions: Key Statistics: 2017
  • Figure 4: Long-Term Growth Drivers
  • Figure 5: Impact Analysis
  • Figure 6: Global Precision Medicine Market Snapshot
  • Figure 7: Dominating Segments of Global Precision Medicine Market, 2017 and 2028
  • Figure 8: Global Precision Medicine Market (by Ecosystem), 2017 and 2028
  • Figure 9: Global Precision Medicine Market, (by Application), 2017 and 2028
  • Figure 10: Global Precision Medicine Market (by Region), 2017 and 2028
  • Figure 11: Notable Areas of Strategic Focus across Influential Countries
  • Figure 12: Strategies Incorporated to Expand the Global Reach
  • Figure 13: Precision Medicine Funding for Academic Institutions and Research Organizations
  • Figure 14: A Persuasive Market Entry Strategy for Diagnostics and Pharma & Biotech Companies to Capitalize on Precision Medicine
  • Figure 15: Plausible Market Penetration Strategy to Shape the Future of Healthcare
  • Figure 16: Go To Market Strategy
  • Figure 17: Value Assessment Frameworks
  • Figure 18: Product/Service Promotion Strategies
  • Figure 19: Precision Medicine: A Trigger to Unfold Innovative Business Model
  • Figure 20: Fixable Gaps in the Field of Precision Medicine
  • Figure 21: Estimated Ratios of Cost per Quality-Adjusted Life Year (QALY) Gained for Precision or Personalized Medicine Tests
  • Figure 22: Impact of Precision Medicine on Researchers, Manufacturers, and Consumers
  • Figure 23: Opportunities and Challenges for Researchers, Providers, and Patients
  • Figure 1.1: Precision Medicine Approach
  • Figure 1.2: Evolution of Precision Medicine Technology
  • Figure 1.3: Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
  • Figure 1.4: Precision Medicine: Remodeling Framework
  • Figure 1.5: Precision Medicine: Enabling Technologies
  • Figure 1.6: Structured Big Data Reporting Benefits
  • Figure 1.7: Generalized Process for the Microarray
  • Figure 2.1: Market Dynamics of Global Precision Medicine Market
  • Figure 2.2: Total Number of Genetic Products in Market
  • Figure 2.3: Total Number of Genetic Products in Market
  • Figure 2.4: % of Patients Whose Tumors Were Driven by Certain Genetic Mutations That Could Be Targets for Specific Drugs
  • Figure 2.5: Gene Therapy Products in Pipeline
  • Figure 2.6: Sales Forecast for Gene Therapy Products (Yescarta and Kymriah), $ Million
  • Figure 2.7: Precision Medicine Deals (2010-2017)
  • Figure 3.1: Competitive Landscape, January 2012-December 2018
  • Figure 3.2: Share of Key Developments and Strategies (January 2012-December 2018)
  • Figure 3.3: Joint Ventures, Partnerships, Agreements, and Collaborations Share by Companies (January 2012-December 2018)
  • Figure 3.4: Product launches, Enhancements, and Upgradation Share by Companies (January 2012-December 2018)
  • Figure 3.5: Product Approvals Share by Companies (January 2012-December 2018)
  • Figure 3.6: Merger and Acquisitions Share by Companies (January 2012-December 2018)
  • Figure 3.7: Business Expansion Share by Companies (January 2012-December 2018)
  • Figure 3.8: Other Developments Share by Companies (January 2012-December 2018)
  • Figure 3.9: Market Share Analysis by Applied Sciences, 2017
  • Figure 3.10: Market Share Analysis by Precision Diagnostics, 2017
  • Figure 3.11: Market Share Analysis by Precision Therapeutics, 2017
  • Figure 3.12: Market Share Analysis by Digital Health and IT, 2017
  • Figure 3.13: Porter's Five Forces Analysis
  • Figure 3.14: Definition of Suppliers and Buyers in the Precision Medicine Market
  • Figure 3.15: Bargaining Power of Suppliers: Overall Impact, 2015-2028
  • Figure 3.16: Bargaining Power of Buyers: Overall Impact, 2015-2028
  • Figure 3.17: Threat of New Entrant: Overall Impact, 2015-2028
  • Figure 3.18: Threat of Substitute Products: Overall Impact, 2014-2028
  • Figure 3.19: Intensity of Competitive Rivalry: Overall Impact, 2015-2028
  • Figure 3.20: Supply Chain Analysis: Global Precision Medicine Market
  • Figure 4.1: Patent Analysis
  • Figure 4.2: Role of FDA in Advancing Precision Medicine
  • Figure 5.1: Precision Medicine: The Ecosystem
  • Figure 5.2: Global Precision Medicine Market (by Ecosystem)
  • Figure 5.3: Global Precision Medicine Market (by Ecosystem), 2017-2028
  • Figure 5.4: Global Precision Medicine Market (by Applied Sciences)
  • Figure 5.5: Global Precision Medicine Market (by Applied Sciences), 2017-2028
  • Figure 5.6: Precision Medicine: Omics Sciences
  • Figure 5.7: Global Precision Medicine Applied Sciences Market (by Type), 2017-2028
  • Figure 5.8: Precision Medicine: Genomics
  • Figure 5.9: Global Precision Medicine Genomics Market, 2017-2028
  • Figure 5.10: Global Precision Medicine Genomics Market (by Technology), 2017-2028
  • Figure 5.11: Global Precision Medicine PCR Market, 2017-2028
  • Figure 5.12: Global Precision Medicine PCR Market (by Product Type), 2017-2028
  • Figure 5.13: Global Precision Medicine PCR Market (by End User), 2017-2028
  • Figure 5.14: Global Precision Medicine PCR Market (by Region), 2017-2028
  • Figure 5.15: Evolution of Next-Generation Sequencing
  • Figure 5.16: Global Precision Medicine NGS Market, 2017-2028
  • Figure 5.17: Global Precision Medicine PM NGS Market (by Product Type), 2017-2028
  • Figure 5.18: Global Precision Medicine NGS Market (by Technology), 2017-2028
  • Figure 5.19: Global Precision Medicine NGS Market (by End User), 2017-2028
  • Figure 5.20: Global Precision Medicine NGS Market (by Region), 2017-2028
  • Figure 5.21: Global Precision Medicine Genome Editing Market, 2017-2028
  • Figure 5.22: Global Precision Medicine Genome Editing Market (by Product Type), 2017-2028
  • Figure 5.23: Global Precision Medicine Genome Editing Market (by End User), 2017-2028
  • Figure 5.24: Global Precision Medicine Genome Editing Market (by Region), 2017-2028
  • Figure 5.25: Global Precision Medicine Other Technologies Market, 2017-2028
  • Figure 5.26: Global Precision Medicine Other Technologies Market (by Region), 2017-2028
  • Figure 5.27: Clinical Applications of Pharmacogenomics Testing
  • Figure 5.28: Role of Biomarkers in Pharmacogenomics
  • Figure 5.29: Role of FDA In Pharmacogenomics
  • Figure 5.30: Global Precision Medicine Pharmacogenomics Market, 2017-2028
  • Figure 5.31: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services), 2017-2028
  • Figure 5.32: Global Precision Medicine Pharmacogenomics Market (by End User), 2017-2028
  • Figure 5.33: Global Precision Medicine Pharmacogenomics Market (by Region), 2017-2028
  • Figure 5.34: Global Precision Medicine Other Applied Sciences Market, 2017-2028
  • Figure 5.35: Precision Medicine: Diagnostics
  • Figure 5.36: Global Precision Medicine Market (by Precision Diagnostics)
  • Figure 5.37: Global Precision Medicine Market (by Precision Diagnostics), 2017-2028
  • Figure 5.38: Global Precision Medicine Diagnostics Market (by Type), 2017-2028
  • Figure 5.39: General Workflow of a Molecular Diagnostic Assay
  • Figure 5.40: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics)
  • Figure 5.41: Global Precision Medicine Molecular Diagnostics Market, 2017-2028
  • Figure 5.42: Global Precision Medicine Molecular Diagnostics Market (by Type), 2017-2028
  • Figure 5.43: Benefits and Risks Associated with NIPT
  • Figure 5.44: Global Precision Medicine NIPT Market, 2017-2028
  • Figure 5.45: Global Precision Medicine NIPT Market (by Platform), 2017-2028
  • Figure 5.46: Global Precision Medicine NIPT Market (by Region), 2017-2028
  • Figure 5.47: Drug and Companion Diagnostics Development Process
  • Figure 5.48: Benefits and Risks Associated with Companion Diagnostics
  • Figure 5.49: Global Precision Medicine Companion Diagnostics Market, 2017-2028
  • Figure 5.50: Global Precision Medicine Companion Diagnostics Market (by Technology), 2017-2028
  • Figure 5.51: Global Precision Medicine Companion Diagnostics Market (by Indication), 2017-2028
  • Figure 5.52: Global Precision Medicine Companion Diagnostics Market (by Region), 2017-2028
  • Figure 5.53: Clinical Applications of Liquid Biopsy
  • Figure 5.54: Global Precision Medicine Liquid Biopsy Market, 2017-2028
  • Figure 5.55: Global Precision Medicine Liquid Biopsy Market (by Indication), 2017-2028
  • Figure 5.56: Global Precision Medicine Liquid Biopsy Market (by Region), 2017-2028
  • Figure 5.57: Global Precision Medicine Other Molecular Diagnostics Market, 2017-2028
  • Figure 5.58: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2017-2028
  • Figure 5.59: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2017-2028
  • Figure 5.60: Global Precision Medicine Medical Imaging Market, 2017-2028
  • Figure 5.61: Global Precision Medicine Medical Imaging Market (by Type), 2017-2028
  • Figure 5.62: Global Precision Medicine Medical Imaging Market (by Region), 2017-2028
  • Figure 5.63: Global Precision Medicine Imaging Analytics Market, 2017-2028
  • Figure 5.64: Global Precision Medicine CADx Market, 2017-2028
  • Figure 5.65: Global Precision Medicine Digital Health and Information Technology Market, 2017-2028
  • Figure 5.66: Global Precision Medicine Digital Health and Information Technology Market (by Type), 2017-2028
  • Figure 5.67: Global Precision Medicine Digital Health and Information Technology Market (by End User), 2017-2028
  • Figure 5.68: Global Precision Medicine Digital Health and Information Technology Market (by Region), 2017-2028
  • Figure 5.69: Global Precision Medicine CDSS Market, 2017-2028
  • Figure 5.70: Big Data Attributes
  • Figure 5.71: Global Precision Medicine Big Data Analytics Market, 2017-2028
  • Figure 5.72: Big Data Analytics: Key Benefits
  • Figure 5.73: Global Precision Medicine IT Infrastructure Market, 2017-2028
  • Figure 5.74: Global Precision Medicine IT Infrastructure Market (by Type), 2017-2028
  • Figure 5.75: Global Precision Medicine Genomics Informatics Market, 2017-2028
  • Figure 5.76: Global Precision Medicine Genomics Informatics Market (by Product Type), 2017-2028
  • Figure 5.77: Global Precision Medicine In-Silico Informatics Market, 2017-2028
  • Figure 5.78: Global Precision Medicine Mobile Health Market, 2017-2028
  • Figure 5.79: Global Precision Medicine Therapeutics Market, 2017-2028
  • Figure 5.80: Global Precision Medicine Therapeutics Market (by Type), 2017-2028
  • Figure 5.81: Global Precision Medicine Clinical Trials Market, 2017-2028
  • Figure 5.82: Global Precision Medicine Clinical Trials Market (by Region), 2017-2028
  • Figure 5.83: Types of Cell Therapy
  • Figure 5.84: Global Precision Medicine Cell Therapy Market, 2017-2028
  • Figure 5.85: Global Precision Medicine Cell Therapy Market (by Region), 2017-2028
  • Figure 5.86: Global Precision Medicine Drug Discovery and Research Market, 2017-2028
  • Figure 5.87: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028
  • Figure 5.88: Types of Gene Therapy
  • Figure 5.89: Types of Gene Therapy
  • Figure 5.90: Global Precision Medicine Gene Therapy Market, 2017-2028
  • Figure 5.91: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028
  • Figure 6.1: Therapeutic Areas in Precision Medicine
  • Figure 6.2: Global Precision Medicine Applications Market, 2017-2028
  • Figure 6.3: Types of Cancer
  • Figure 6.4: Global Precision Medicine Oncology Market, 2017-2028
  • Figure 6.5: Global Precision Medicine Infectious Diseases Market, 2017-2028
  • Figure 6.6: Number of Deaths by Top 18 Infectious Diseases, 2015
  • Figure 6.7: Global Precision Medicine Neurology/Physiatry Market, 2017-2028
  • Figure 6.8: Global Precision Medicine Cardiovascular Market, 2017-2028
  • Figure 6.9: Global Precision Medicine Lifestyle and Endocrinology Market, 2017-2028
  • Figure 6.10: Global Precision Medicine Gastroenterology Market, 2017-2028
  • Figure 6.11: Global Precision Medicine Other Applications Market, 2017-2028
  • Figure 7.1: Global Precision Medicine Market (by Region)
  • Figure 7.2: Global Precision Medicine Market (by Region), 2017 and 2028
  • Figure 7.3: Global Precision Medicine Market (by Region), 2017-2028
  • Figure 7.4: North America Precision Medicine Market, 2017-2028
  • Figure 7.5: North America Precision Medicine Market (by Country), 2017-2028
  • Figure 7.6: North America Precision Medicine Market (by Ecosystem), 2017-2028
  • Figure 7.7: The U.S. Precision Medicine Market, 2017-2028
  • Figure 7.8: Canada Precision Medicine Market, 2017-2028
  • Figure 7.9: Europe Precision Medicine Market, 2017-2028
  • Figure 7.10: Europe Precision Medicine Market (by Country), 2017-2028
  • Figure 7.11: Europe Precision Medicine Market (by Ecosystem), 2017-2028
  • Figure 7.12: Germany Precision Medicine Market, 2017-2028
  • Figure 7.13: France Precision Medicine Market, 2017-2028
  • Figure 7.14: Italy Precision Medicine Market, 2017-2028
  • Figure 7.15: The U.K. Precision Medicine Market, 2017-2028
  • Figure 7.16: Spain Precision Medicine Market, 2017-2028
  • Figure 7.17: Rest-of-Europe Precision Medicine Market, 2017-2028
  • Figure 7.18: Asia-Pacific Precision Medicine Market, 2017-2028
  • Figure 7.19: Asia-Pacific Precision Medicine Market (by Country), 2017-2028
  • Figure 7.20: Asia-Pacific Precision Medicine Market (by Ecosystem), 2017-2028
  • Figure 7.21: China Precision Medicine Market, 2017-2028
  • Figure 7.22: Japan Precision Medicine Market, 2017-2028
  • Figure 7.23: Australia Precision Medicine Market, 2017-2028
  • Figure 7.24: India Precision Medicine Market, 2017-2028
  • Figure 7.25: Rest-of- Asia-Pacific Precision Medicine Market, 2017-2028
  • Figure 7.26: Latin America Precision Medicine Market, 2017-2028
  • Figure 7.27: Latin America Precision Medicine Market (by Country), 2017-2028
  • Figure 7.28: Latin America Precision Medicine Market (by Ecosystem), 2017-2028
  • Figure 7.29: Brazil Precision Medicine Market, 2017-2028
  • Figure 7.30: Mexico Precision Medicine Market, 2017-2028
  • Figure 7.31: Rest-of-Latin America Precision Medicine Market, 2017-2028
  • Figure 7.32: Rest-of-the-World Precision Medicine Market, 2017-2028
  • Figure 7.33: Major Countries in the Middle East Precision Medicine Market
  • Figure 8.1: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017
  • Figure 8.2: Abbott Laboratories: Revenue (by Business Segment), 2015-2017
  • Figure 8.3: Abbott Laboratories: Revenue (by Region), 2015-2017
  • Figure 8.4: Abbott Laboratories R&D Expenditure, 2015-2017
  • Figure 8.5: Amgen Inc.: Overall Financials, 2015-2017
  • Figure 8.6: Amgen Inc.: Revenue (by Region), 2015-2017
  • Figure 8.7: Amgen Inc. R&D Expenditure, 2014-2017
  • Figure 8.8: ANGLE plc: Overall Financials, 2015-2017
  • Figure 8.9: ANGLE plc: Revenue (by Region), 2015-2017
  • Figure 8.10: ANGLE plc R&D Expenditure, 2014-2017
  • Figure 8.11: Astellas Pharma Inc.: Overall Financials, 2015-2017
  • Figure 8.12: Astellas Pharma Inc.: Revenue (by Region), 2015-2017
  • Figure 8.13: Astellas Pharma Inc. R&D Expenditure, 2015-2017
  • Figure 8.14: Astra Zeneca PLC : Overall Financials, 2015-2017
  • Figure 8.15: Astra Zeneca PLC: Revenue (by Business Segment), 2015-2017
  • Figure 8.16: Astra Zeneca PLC: Revenue (by Region), 2015-2017
  • Figure 8.17: Astra Zeneca PLC R&D Expenditure, 2014-2017
  • Figure 8.18: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017
  • Figure 8.19: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2015-2017
  • Figure 8.20: Bio-Rad Laboratories, Inc: Revenue (by Region), 2015-2017
  • Figure 8.21: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017
  • Figure 8.22: bioMérieux SA.: Overall Financials, 2015-2017
  • Figure 8.23: bioMérieux SA.: Revenue (by Business Segment), 2015-2017
  • Figure 8.24: bioMérieux SA.: Revenue (by Region), 2015-2017
  • Figure 8.25: bioMérieux SA. R&D Expenditure, 2014-2017
  • Figure 8.26: Bristol-Myers Squibb Company: Overall Financials, 2015-2017
  • Figure 8.27: Bristol-Myers Squibb Company: Revenue (by Region), 2015-2017
  • Figure 8.28: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017
  • Figure 8.29: Canon Inc.: Overall Financials, 2015-2017
  • Figure 8.30: Canon Inc.: Revenue (by Segment), 2015-2017
  • Figure 8.31: Canon Inc.: Revenue (by Region), 2015-2017
  • Figure 8.32: Canon Inc.: R&D Expenditure, 2015-2017
  • Figure 8.33: Danaher Corporation: Overall Financials, 2015-2017
  • Figure 8.34: Danaher Corporation: Revenue (by Business Segment), 2015-2017
  • Figure 8.35: Danaher Corporation: Revenue (by Region), 2015-2017
  • Figure 8.36: Danaher Corporation R&D Expenditure, 2014-2017
  • Figure 8.37: Eli Lilly and Company Limited: Overall Financials, 2015-2017
  • Figure 8.38: Eli Lilly and Company Limited: Revenue (by Business Segment), 2015-2017
  • Figure 8.39: Eli Lilly and Company Limited: Revenue (by Region), 2015-2017
  • Figure 8.40: Eli Lilly and Company Limited R&D Expenditure, 2014-2017
  • Figure 8.41: F.Hoffman-LA Roche AG: Overall Financials, 2015-2017
  • Figure 8.42: F.Hoffman-LA Roche AG: Revenue (by Business Segment), 2015-2017
  • Figure 8.43: F.Hoffman-LA Roche AG : Revenue (by Region), 2015-2017
  • Figure 8.44: F.Hoffman-LA Roche AG R&D Expenditure, 2014-2017
  • Figure 8.45: GE Corporation Limited: Overall Financials, 2015-2017
  • Figure 8.46: GE Corporation: Revenue (by Business Segment), 2015-2017
  • Figure 8.47: GE Corporation: Revenue (by Region), 2015-2017
  • Figure 8.48: GE Corporation R&D Expenditure, 2014-2017
  • Figure 8.49: Gilead Sciences, Inc.: Overall Financials, 2015-2017
  • Figure 8.50: Gilead Sciences, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 8.51: Gilead Sciences, Inc.: Revenue (by Region), 2015-2017
  • Figure 8.52: Gilead Sciences, Inc. R&D Expenditure, 2014-2017
  • Figure 8.53: GlaxoSmithKline Plc: Overall Financials, 2015-2017
  • Figure 8.54: GlaxoSmithKline Plc: Revenue (by Business Segment), 2015-2017
  • Figure 8.55: GlaxoSmithKline Plc: Revenue (by Region), 2015-2017
  • Figure 8.56: GlaxoSmithKline Plc R&D Expenditure, 2014-2017
  • Figure 8.57: IBM Corporation: Overall Financials, 2015-2017
  • Figure 8.58: IBM Corporation: Revenue (by Business Segment), 2015-2017
  • Figure 8.59: IBM Corporation: Revenue (by Region), 2015-2017
  • Figure 8.60: IBM Corporation R&D Expenditure, 2014-2017
  • Figure 8.61: Illumina, Inc.: Overall Financials, 2015-2017
  • Figure 8.62: Illumina, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 8.63: Illumina, Inc.: Revenue (by Region), 2015-2017
  • Figure 8.64: Illumina, Inc. R&D Expenditure, 2014-2017
  • Figure 8.65: Johnson and Johnson: Overall Financials, 2015-2017
  • Figure 8.66: Johnson and Johnson: Revenue (by Business Segment), 2015-2017
  • Figure 8.67: Johnson and Johnson Revenue (by Region), 2015-2017
  • Figure 8.68: Johnson and Johnson R&D Expenditure, 2014-2017
  • Figure 8.69: Konica Minolta, Inc.: Overall Financials, 2015-2017
  • Figure 8.70: Konica Minolta, Inc.: Revenue (by Segment), 2015-2017
  • Figure 8.71: Konica Minolta, Inc.: Revenue (by Region), 2015-2017
  • Figure 8.72: Konica Minolta, Inc.: R&D Expenditure, 2015-2017
  • Figure 8.73: Lab Corporation of America: Overall Financials, 2015-2017
  • Figure 8.74: Lab Corporation of America: Revenue (by Business Segment), 2015-2017
  • Figure 8.75: Lab Corporation of America: Revenue (by Region), 2015-2017
  • Figure 8.76: MDx Health, Inc.: Overall Financials, 2015-2017
  • Figure 8.77: MDx Health, Inc. R&D Expenditure, 2014-2017
  • Figure 8.78: Merck & Co., Inc.: Overall Financials, 2015-2017
  • Figure 8.79: Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 8.80: Merck & Co., Inc.: Revenue (by Region), 2015-2017
  • Figure 8.81: Merck & Co., Inc. R&D Expenditure, 2015-2017
  • Figure 8.82: Myriad Genetics, Inc.: Overall Financials, 2015-2017
  • Figure 8.83: Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 8.84: Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
  • Figure 8.85: Myriad Genetics, Inc. R&D Expenditure, 2015-2017
  • Figure 8.86: Novartis AG: Overall Financials, 2015-2017
  • Figure 8.87: Novartis AG: Revenue (by Business Segment), 2015-2017
  • Figure 8.88: Novartis AG: Revenue (by Region), 2015-2017
  • Figure 8.89: Novartis AG R&D Expenditure, 2015-2017
  • Figure 8.90: Oracle Corporation: Overall Financials, 2015-2017
  • Figure 8.91: Oracle Corporation: Revenue (by Region), 2015-2017
  • Figure 8.92 Oracle Corporation R&D Expenditure, 2015-2017
  • Figure 8.93: Pacific Biosciences of California, Inc.: Overall Financials, 2015-2017
  • Figure 8.94: Pacific Biosciences of California, Inc.: Revenue (by Region), 2015-2017
  • Figure 8.95: Pacific Biosciences of California, Inc. R&D Expenditure, 2015-2017
  • Figure 8.96: Pfizer, Inc.: Overall Financials, 2015-2017
  • Figure 8.97: Pfizer, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 8.98: Pfizer, Inc.: Revenue (by Region), 2015-2017
  • Figure 8.99: Pfizer, Inc. R&D Expenditure, 2015-2017
  • Figure 8.100: QIAGEN N.V: Overall Financials, 2015-2017
  • Figure 8.101: QIAGEN N.V: Revenue (by Business Segment), 2015-2017
  • Figure 8.102: QIAGEN N.V: Revenue (by Region), 2015-2017
  • Figure 8.103: QIAGEN N.V R&D Expenditure, 2015-2017
  • Figure 8.104: Quest Diagnostics Inc.: Overall Financials, 2015-2017
  • Figure 8.105: Quest Diagnostics Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 8.106: Quest Diagnostics Inc.: Revenue (by Region), 2015-2017
  • Figure 8.107: Sanofi SA: Overall Financials, 2015-2017
  • Figure 8.108: Sanofi SA: Revenue (by Business Segment), 2015-2017
  • Figure 8.109: Sanofi SA: Revenue (by Region), 2015-2017
  • Figure 8.110 Sanofi SA R&D Expenditure, 2015-2017
  • Figure 8.111: Sysmex Corporation: Overall Financials, 2015-2017
  • Figure 8.112: Sysmex Corporation: Revenue (by Business Segment), 2015-2017
  • Figure 8.113: Sysmex Corporation R&D Expenditure, 2015-2017
  • Figure 8.114: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2015-2017
  • Figure 8.115: Teva Pharmaceuticals Industries Ltd.: Revenue (by Business Segment), 2015-2017
  • Figure 8.116: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2015-2017
  • Figure 8.117: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2015-2017
  • Figure 8.118: Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
  • Figure 8.119: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 8.120: Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
  • Figure 8.121 Thermo Fisher Scientific Inc. R&D Expenditure, 2015-2017
  • Figure 8.122: TrovaGene,Inc.: Overall Financials, 2015-2017
  • Figure 9.1: Global Precision Medicine Market Segmentation
  • Figure 9.2: Figure Scope
  • Figure 9.3: Key data points from primary resources
  • Figure 9.4: Key data points from secondary resources
  • Figure 9.5: Top-down Approach (Segment-wise Analysis)
  • Figure 9.6: Bottom-Up Approach (Segmental Analysis)
  • Figure 9.7: Research Methodology Snapshot
  • Figure 9.8: Assumptions and Limitations
  • Figure 9.9: Considered Factors for Data Prediction and Modelling
目次
Product Code: BH002D

Global Precision Medicine Market to Reach $216.75 Billion by 2028

Various advancements in the life sciences industry have paved the way for development of several precision medicine solutions. It is one of the most modernized trends in the healthcare industry that has projected tremendous level of progress in the last few years. The completion of the Human Genome project in 2003 and the precision medicine initiative in 2015 provided a path of opportunity to introduce new scientific, medical, and business models in the precision medicine market. The sole idea behind the development of precision medicine solution is to provide targeted therapies to population based on their genomic structure. Therefore, the application of 'omics' (genomics, proteomics, transcriptomics) analysis is widely used in this market. The precision medicine market is a multibillion market which consists of innumerable companies involved in the research and development, manufacturing and commercialization of several novel drugs and diagnostic kits to boost the Precision Medicine workflow.

Currently, the precision medicine market is gaining preference among the masses due to the growth of personal healthcare devices and integration of smart technologies in the healthcare system. In addition, increasing collaborations and partnerships between various ecosystem players are aiding in the robust growth of the precision medicine market. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), government support and regulations, which consequently, have created a demand for the precision medicine solutions. Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The primary aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases, among others.

The purpose of this study is to gain a holistic view of the precision medicine market in terms of various influencing factors, such as recent trends, technological advancements, and role of various key stakeholders in the market. The report constitutes an in-depth study of the global precision medicine market, including a thorough analysis of the products across different regions. The study also presents a detailed analysis of the market trends, and the market size for the period 2017-2028, wherein 2017 is the base year, and the years from 2018 to 2028 constitute the forecast period. The report covers all the prevalent trends which are expected to play a significant role in the growth of the market over the forecast period. It also highlights various drivers, restraints, challenges, and opportunities which are expected to influence the market's growth during the forecast period. The report is focused on the global precision medicine market; ecosystem and technology, application, their market dynamics, growth prospect mapping, SWOT analysis, Porter's Five Forces, market share analysis, pipeline analysis, and country-wise analysis.

The study provides a holistic perspective on the market growth, in terms of revenue estimates, across different geographies which include North America, Europe, Asia-Pacific (APAC), Latin America, and Rest of the World (RoW). The report provides cross-sectional analysis of the global precision medicine market in terms of market estimates, and projections, for all the segments across different geographical regions. The regions have been further segmented to cover the in-depth country level analysis. The North American region has been segmented into the U.S., and Canada. Similarly, Europe has been further segmented into the U.K., Germany, France, Spain, Italy, and Rest of Europe. Asia Pacific has been segmented into China, Japan, Australia, India, and Rest of Asia Pacific. Latin America has been segmented into Brazil, Mexico, and Rest of Latin America. Moreover, Rest of the World (RoW) has been further segmented into Middle East and Africa.

Key questions answered in the report

  • What are the major market drivers, challenges, and opportunities in the global precision medicine market?
  • What are the underlying structures resulting in the emerging trends within the precision medicine market?
  • What was the market value of the leading segments and sub-segments of the global precision medicine market in 2017?
  • How will each segment of the global precision medicine market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2028?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period 2018- 2028?
  • What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?
  • What are the key ecosystem type in the global precision medicine market? What are the major benefits of each type?
  • How has the market been segmented on the basis of application type? Which application type is dominating the global precision medicine market and what is the reason behind such domination?
  • Which ecosystem type is having the most promising growth and in which application type?
  • What is the market share of each of the companies in the global precision medicine market and what are their contributions?
  • What is the scope of each type of ecosystem in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
  • What is the growth potential of precision medicine in each region, including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
  • How many countries are covered in each geographical region? Which country is currently dominating the precision medicine market?

The key players which have been contributing significantly to the precision medicine market include Abbott Laboratories, Almac Group, Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, ASURAGEN, INC., bioMerieux SA, BRISTOL-MYERS SQUIBB COMPANY, CETICS Healthcare Technologies GmbH, Eli-Lilly and Company, F. Hoffmann-La Roche AG, GE Healthcare, GlaxoSmithKline, IBM Corporation, Illumina, Inc., Intomics A/S, JOHNSON & JOHNSON, Laboratory Corporation of America, Merck KGaA, Novartis AG, Pfizer, Inc., QIAGEN, Quest Diagnostics, SANOFI, Teva Pharmaceuticals Limited, and Thermo Fisher Scientific, among others.

Executive Summary

There has been a continuous search in the medical world for better treatment and prevention approaches for various infectious and non-infectious diseases, paving the way for the most awaited changes in personalized medicines. In recent years, the impressive research on biologics for the development of DNA, the study of the human genome, and the development of precision diagnostic tools and software has opened new hopes to develop promising precision medicine for different types of cancers, infectious diseases, and rare and orphan diseases. Advancements in genome analysis, especially in the development of vaccine platforms and accelerating adoption of companion diagnostics in routine healthcare procedures, coupled with ongoing clinical trials, have resulted in the evolution of precision medicine - a healthcare model (comprising treatment, practices, and healthcare products like medicine) that is customized as per the patient.

Precision medicine has significantly positioned itself as the hotspot of mainstream medicine. With aggressive technological developments, such as next-generation sequencing and fierce competition in the field of targeted molecular therapy, precision medicine portrays itself as a sophisticated medical care model while simultaneously opening avenues for public health care. However, despite its proven potential, the technology is still in its infancy and needs to evolve while overcoming many deficiencies and challenges.

On the other hand, immense expectations are associated with precision medicine in terms of its capability to define Diseases, based on molecular characteristics and environmental susceptibility factors. The fulfilment of those expectations need pre-requisites such as the construction of a novel data network, integration of clinical data from patients, and further expansion of research aimed at finding the molecular makeup of diseases. Also, multi-omics analysis and cross-industry collaborations will be instrumental at realizing the benefits of precision medicine with its fullest potential. To, bolster precision medicine, genomic sequencing is of utmost importance, and since 2003 (after the completion of Human Genome Project), genomic sequencing has attained great strides in terms of both cost and time. This genome sequencing technology is so advanced now that a single genome can be sequenced under $1000 within a day. The cost has plummeted to approximately three million times and the time taken for the process has reduced 3,000 times since the first genome was ever sequenced.

The purpose of BIS Research study on global precision medicine market is to gain a holistic view of the precision medicine market in terms of various influencing factors, such as the trends, regulatory frameworks, and technological advancements. The report constitutes a detailed study of the different kinds of products and technologies associated with the global precision medicine market. The market has been segmented into "ecosystem", "application type", and "region". The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in the reader form well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

The global precision medicine market is anticipated to reach $216.75 billion by 2028, witnessing a CAGR of 10.64% in the forecast period 2018-2028. Some of the factors such as the emergence of liquid biopsy, increasing demand for multiplex assays to target emerging diseases, reduced adverse drug reactions through pharmacogenomics testing, and increasing focus on target-based therapies are acting as significant factors propelling the growth of the global precision medicine market.

In terms of ecosystem, the global precision medicine market is dominated by applied sciences. This dominance can be attributed to the ongoing advancements in the field of human genomics and innovation of new healthcare technologies such as next-generation sequencing, high throughput screening (HTS), and digital polymerase chain reaction (PCR). The completion of the first human genome project in the 1990s has created the platform for the development of further enhanced pharmacogenomics solutions in applied sciences. At present, government initiatives are focused on launching a large number of genomic tests and drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology and cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.

In terms of application type, the global precision medicine market is dominated by oncology. In 2017, the market for oncology was valued $38.01 billion. Cancer is classified to be a disease of genetic mutation, as a result of genetic changes. Technological advancement has generated a better understanding of tumor and led to more effective treatment strategies that are personalized to the genetic profile of patients suffering from different types of cancer.

In terms of regional potential, North America is the leading contributor to the global precision medicine market and contributed approximately 47% of the global market values in 2017. This can be attributed to increasing usage of genomics and pharmacogenomics in the development of personalized medicines, and high income of patients to afford costly diagnostic and genetic tests. Also, in the year 2015, the launch of Precision Medicine Initiative (PMI) by the then U.S. president, Barack Obama, completely revolutionized the process of healthcare delivery in the nation. The initiative was aimed at irradiating the already existing "one-size-fits-all" approach of treatment and hence improve patient outcomes while minimalizing healthcare costs. In financial terms, the initiative was worth $215 million and significantly accelerated the discovery of biomedical tools, knowledge, and therapies to assist clinicians to come up with the treatment that best serves the individual need of the patients.

The key players who have been contributing significantly to the global precision medicine market are Pfizer, Inc., Merck & Co., Inc., Abbott Laboratories, GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Almac Group Ltd., Bio-Rad Laboratories, Inc. Johnson and Johnson, and bioMerieux S.A., among others.

Table of Contents

Executive Summary

1 Market Overview

  • 1.1 Introduction
  • 1.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine
  • 1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
  • 1.4 Initiatives and Programs
  • 1.5 Assumptions and Limitations for Market Size Calculations
  • 1.6 Precision Medicine: Enabling Technologies
    • 1.6.1 Innovators
      • 1.6.1.1 3D DNA Printing
        • 1.6.1.1.1 Introduction
        • 1.6.1.1.2 Role of 3D DNA Printing
      • 1.6.1.2 RNA-Seq
        • 1.6.1.2.1 Introduction
        • 1.6.1.2.2 Role of RNA-Seq in Precision Medicine
        • 1.6.1.2.3 Key Players
      • 1.6.1.3 4D Molecular Imaging
        • 1.6.1.3.1 Introduction
        • 1.6.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
        • 1.6.1.3.3 Key Players
    • 1.6.2 Early Adopters
      • 1.6.2.1 CRISPR
        • 1.6.2.1.1 Introduction
        • 1.6.2.1.2 Role of CRISPR in Precision Medicine
        • 1.6.2.1.3 Key Players
      • 1.6.2.2 Blockchain
        • 1.6.2.2.1 Introduction
        • 1.6.2.2.2 Role of Blockchain in Precision Medicine
        • 1.6.2.2.3 Key Players
      • 1.6.2.3 Imaging Informatics
        • 1.6.2.3.1 Introduction
        • 1.6.2.3.2 Role of Imaging Informatics in Precision Medicine
        • 1.6.2.3.3 Key Players
    • 1.6.3 Early Majority
      • 1.6.3.1 Artificial Intelligence (AI)
        • 1.6.3.1.1 Introduction
        • 1.6.3.1.2 Role of Artificial Intelligence in Precision Medicine
        • 1.6.3.1.3 Key Players
      • 1.6.3.2 Circulating free DNA (cfDNA)
        • 1.6.3.2.1 Introduction
        • 1.6.3.2.2 Role of cfDNA in Precision Medicine
        • 1.6.3.2.3 Key Players
      • 1.6.3.3 Big Data
        • 1.6.3.3.1 Introduction
        • 1.6.3.3.2 Role of Big Data in Precision Medicine
        • 1.6.3.3.3 Key Players
      • 1.6.3.4 Next-Generation Sequencing (NGS)
        • 1.6.3.4.1 Introduction
        • 1.6.3.4.2 Role of NGS in Precision Medicine
        • 1.6.3.4.3 Key Players
      • 1.6.3.5 Health Informatics
        • 1.6.3.5.1 Introduction
        • 1.6.3.5.2 Role of Health informatics in Precision Medicine
        • 1.6.3.5.3 Key players
      • 1.6.3.6 Bioinformatics
        • 1.6.3.6.1 Introduction
        • 1.6.3.6.2 Role of Bioinformatics in Precision Medicine
        • 1.6.3.6.3 Key Players
    • 1.6.4 Late Majority
      • 1.6.4.1 Polymerase Chain Reactions (PCR)
        • 1.6.4.1.1 Introduction
        • 1.6.4.1.2 Role of PCR in Precision Medicine
        • 1.6.4.1.3 Key players
      • 1.6.4.2 Microarray
        • 1.6.4.2.1 Role of Microarray in Precision Medicine
        • 1.6.4.2.2 Key Players

2 Market Dynamics

  • 2.1 Impact Analysis
  • 2.2 Market Drivers
    • 2.2.1 Advancement of Sequencing Technologies
    • 2.2.2 Rising Prevalence of Chronic Diseases
    • 2.2.3 Growing Demand for Preventive Care
    • 2.2.4 Shifting the Significance in Medicine, from Reaction to Prevention
    • 2.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test
    • 2.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe
  • 2.3 Market Restraints
    • 2.3.1 Unified Framework for Data Integration
    • 2.3.2 Limited Knowledge About Precision Medicine Application
    • 2.3.3 Lack of Robust Reimbursement Landscape
    • 2.3.4 Regulatory Hurdles
  • 2.4 Market Opportunities
    • 2.4.1 Targeted Gene Therapy
    • 2.4.2 Expansion into the Emerging Markets
    • 2.4.3 Collaboration and Partnerships Across Value Chain Would Accelerate the Market Entry

3 Competitive Insights

  • 3.1 Key Developments and Strategies
    • 3.1.1 Joint Ventures, Partnerships, Agreements, and Collaborations
    • 3.1.2 Product launches, Enhancements, and Upgradation
    • 3.1.3 Product Approvals
    • 3.1.4 Merger and Acquisitions
    • 3.1.5 Business Expansion
    • 3.1.6 Other Developments
  • 3.2 Market Share Analysis
    • 3.2.1 Market Share Analysis by Applied Sciences, 2017
    • 3.2.2 Market Share Analysis by Precision Diagnostics, 2017
    • 3.2.3 Market Share Analysis by Precision Therapeutics, 2017
    • 3.2.4 Market Share Analysis by Digital Health and IT, 2017
  • 3.3 Industry Attractiveness
    • 3.3.1 Definition of Suppliers and Buyers in the Precision Medicine Market
    • 3.3.2 Bargaining Power of Suppliers
    • 3.3.3 Bargaining Power of Buyers
    • 3.3.4 Threat of New Entrants
    • 3.3.5 Threat of Substitute Products
    • 3.3.6 Intensity of Competitive Rivalry
  • 3.4 Supply Chain Analysis

4 Industry Insights

  • 4.1 Patent Analysis
  • 4.2 Legal Requirements and Regulations
  • 4.3 Pipeline Analysis

5 Global Precision Medicine Market (by Ecosystem)

  • 5.1 Overview
  • 5.2 Applied Sciences
    • 5.2.1 Genomics
      • 5.2.1.1 Polymerase Chain Reaction (PCR)
      • 5.2.1.2 Precision Medicine Next-Generation Sequencing (PM NGS)
      • 5.2.1.3 Genome Editing
      • 5.2.1.4 Other Technologies
    • 5.2.2 Pharmacogenomics
    • 5.2.3 Other Applied Sciences
  • 5.3 Precision Diagnostics
    • 5.3.1 Molecular Diagnostics (MDx)
      • 5.3.1.1 Non-invasive Prenatal Testing (NIPT)
      • 5.3.1.2 Companion Diagnostics
      • 5.3.1.3 Liquid Biopsy
      • 5.3.1.4 Other Molecular Diagnostics
    • 5.3.2 Medical Imaging
      • 5.3.2.1 Imaging Analytics
      • 5.3.2.2 Imaging Computer-Aided Detection (CADx)
  • 5.4 Digital Health and Information Technology
    • 5.4.1 Clinical Decision Support Systems (CDSS)
    • 5.4.2 Big Data Analytics
    • 5.4.3 IT Infrastructure
    • 5.4.4 Genomics Informatics
    • 5.4.5 In-Silico Informatics
    • 5.4.6 Mobile Health
  • 5.5 Precision Therapeutics
    • 5.5.1 Clinical Trials
    • 5.5.2 Cell Therapy
    • 5.5.3 Drug Discovery and Research
    • 5.5.4 Gene Therapy

6 Global Precision Medicine Market (by Application)

  • 6.1 Overview
  • 6.2 Oncology
    • 6.2.1 Government Initiatives
    • 6.2.2 Key Insights
    • 6.2.3 Drivers and Challenges
    • 6.2.4 Cancer Precision Medicine Drugs and Indications
    • 6.2.5 Recent Key Developments
  • 6.3 Infectious Diseases
    • 6.3.1 Infectious Diseases Precision Medicine Drugs and Indications
  • 6.4 Neurology/Physiatry
    • 6.4.1 Neurology Precision Medicine Drugs and Indications
  • 6.5 Cardiovascular
    • 6.5.1 Cardiovascular Precision Medicine Drugs/Tests/ and Indications
  • 6.6 Lifestyle and Endocrinology
    • 6.6.1 Endocrinology Precision Medicine Drugs and Indications
  • 6.7 Gastroenterology
    • 6.7.1 Gastroenterology Precision Medicine Drugs and Indications
  • 6.8 Other Applications
    • 6.8.1 Precision Drugs for Other Applications

7 Global Precision Medicine Market (by Region)

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 North America Precision Medicine Market Dynamics
    • 7.2.2 The U.S.
      • 7.2.2.1 Market Statistics
      • 7.2.2.2 Overview of Precision Medicine
      • 7.2.2.3 Key Trends
      • 7.2.2.4 Promoting Factors
      • 7.2.2.5 Recent Key Developments
      • 7.2.2.6 Funding Scenario/Investments
      • 7.2.2.7 Regulatory Scenario
      • 7.2.2.8 Key Players
    • 7.2.3 Canada
      • 7.2.3.1 Market Statistics
      • 7.2.3.2 Overview of Precision Medicine
      • 7.2.3.3 Key Trends
      • 7.2.3.4 Promoting Factors
      • 7.2.3.5 Recent Key Developments
      • 7.2.3.6 Funding Scenario
      • 7.2.3.7 Regulatory Scenario
      • 7.2.3.8 Key Players
  • 7.3 Europe
    • 7.3.1 Europe Precision Medicine Market Dynamics
    • 7.3.2 Germany
      • 7.3.2.1 Market Statistics
      • 7.3.2.2 Overview of Precision Medicine
      • 7.3.2.3 Key Trends
      • 7.3.2.4 Promoting Factors
      • 7.3.2.5 Recent Key Developments
        • 7.3.2.5.1 Key Players
    • 7.3.3 France
      • 7.3.3.1 Market Statistics
      • 7.3.3.2 Overview of Precision Medicine
      • 7.3.3.3 Key Trends
      • 7.3.3.4 Promoting Factors
      • 7.3.3.5 Recent Key Developments
      • 7.3.3.6 Key Players
    • 7.3.4 Italy
      • 7.3.4.1 Market Statistics
      • 7.3.4.2 Overview of Precision Medicine
      • 7.3.4.3 Key Trends
      • 7.3.4.4 Promoting Factors
      • 7.3.4.5 Recent Key Developments
      • 7.3.4.6 Funding Scenario/Investments
    • 7.3.5 The U.K.
      • 7.3.5.1 Market Statistics
      • 7.3.5.2 Overview of Precision Medicine
      • 7.3.5.3 Key Trends
      • 7.3.5.4 Promoting Factors
      • 7.3.5.5 Recent Key Developments
      • 7.3.5.6 Funding Scenario/Investments
      • 7.3.5.7 Key Players
    • 7.3.6 Spain
      • 7.3.6.1 Market Statistics
      • 7.3.6.2 Overview of Precision Medicine
      • 7.3.6.3 Key Trends
      • 7.3.6.4 Promoting Factors
      • 7.3.6.5 Recent Key Developments
      • 7.3.6.6 Key Players
    • 7.3.7 Rest-of-Europe
      • 7.3.7.1 Market Statistics
      • 7.3.7.2 Switzerland
  • 7.4 Asia-Pacific (APAC)
    • 7.4.1 Asia-Pacific Precision Medicine Market Dynamics
      • 7.4.1.1 China
      • 7.4.1.2 Market Statistics
      • 7.4.1.3 Overview of Precision Medicine
      • 7.4.1.4 Key Trends
      • 7.4.1.5 Promoting Factors
      • 7.4.1.6 Recent Key Developments
      • 7.4.1.7 Key Players
    • 7.4.2 Japan
      • 7.4.2.1 Market Statistics
      • 7.4.2.2 Overview of Precision Medicine
      • 7.4.2.3 Key Trends
      • 7.4.2.4 Promoting Factors
      • 7.4.2.5 Recent Key Developments
      • 7.4.2.6 Reimbursement Scenario
      • 7.4.2.7 Key Players
    • 7.4.3 Australia
      • 7.4.3.1 Market Statistics
      • 7.4.3.2 Overview of Precision Medicine
      • 7.4.3.3 Key Trends
      • 7.4.3.4 Promoting Factors
      • 7.4.3.5 Recent Key Developments
      • 7.4.3.6 Regulatory Scenario
      • 7.4.3.7 Key Players
    • 7.4.4 India
      • 7.4.4.1 Market Statistics
      • 7.4.4.2 Overview of Precision Medicine
      • 7.4.4.3 Key Trends
      • 7.4.4.4 Promoting Factors
      • 7.4.4.5 Recent Key Developments
      • 7.4.4.6 Key Players
    • 7.4.5 Rest-of-Asia-Pacific (RoAPAC)
      • 7.4.5.1 Market Statistics
      • 7.4.5.2 Singapore
      • 7.4.5.2.1 Regulatory Framework
      • 7.4.5.3 South Korea
      • 7.4.5.4 Vietnam
  • 7.5 Latin America
    • 7.5.1 Latin America Precision Medicine Market Dynamics
    • 7.5.2 Brazil
      • 7.5.2.1 Market Statistics
      • 7.5.2.2 Overview of Precision Medicine
    • 7.5.3 Mexico
      • 7.5.3.1 Market Statistics
      • 7.5.3.2 Overview of Precision Medicine
      • 7.5.3.3 Recent Key Developments
    • 7.5.4 Rest-of-Latin America (RoLA)
      • 7.5.4.1 Market Statistics
  • 7.6 Rest-of-the-World (RoW)
    • 7.6.1 Market Statistics
      • 7.6.1.1 Middle East Precision Market Dynamics
      • 7.6.1.2 Africa Precision Medicine Market Dynamics
      • 7.6.1.3 Israel
      • 7.6.1.4 Saudi Arabia
      • 7.6.1.5 United Arab Emirates
      • 7.6.1.6 South Africa
      • 7.6.1.7 Russia

8 Company Profile

  • 8.1 Abbott Laboratories.
    • 8.1.1 Company Overview
    • 8.1.2 Role of Abbott Laboratories, Inc.in the Global Precision Medicine Market
    • 8.1.3 Key Insights about Financial Health of the Company
    • 8.1.4 SWOT Analysis
  • 8.2 Almac Group Ltd.
    • 8.2.1 Company Overview
    • 8.2.2 Role of Almac Group Ltd. in the Global Precision Medicine Market
    • 8.2.3 SWOT Analysis
  • 8.3 Amgen Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Role of Amgen Inc. in the Global Precision Medicine Market
    • 8.3.3 Key Insights about Financial Health of the Company
    • 8.3.4 SWOT Analysis
  • 8.4 ANGLE plc
    • 8.4.1 Company Overview
    • 8.4.2 Role of ANGLE plc in the Global Precision Medicine Market
    • 8.4.3 Key Insights about Financial Health of the Company
    • 8.4.4 SWOT Analysis
  • 8.5 Astellas Pharma Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Role of Astellas Pharma Inc.in the Global Precision Medicine Market
    • 8.5.3 Key Insights about Financial Health of the Company
    • 8.5.4 SWOT Analysis
  • 8.6 Astra Zeneca PLC
    • 8.6.1 Company Overview
    • 8.6.2 Role of Astra Zeneca PLC in the Global Precision Medicine Market
    • 8.6.3 Key Insights about Financial Health of the Company
    • 8.6.4 SWOT Analysis
  • 8.7 ASURAGEN INC.
    • 8.7.1 Company Overview
    • 8.7.2 Role of ASURAGEN Inc. in the Global Precision Medicine Market
    • 8.7.3 SWOT Analysis
  • 8.8 Bio-Rad Laboratories, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Role of Bio-Rad Laboratories, Inc.in the Global Precision Medicine Market
    • 8.8.3 Key Insights about Financial Health of the Company
    • 8.8.4 SWOT Analysis
  • 8.9 bioMérieux SA.
    • 8.9.1 Company Overview
    • 8.9.2 Role of bioMérieux SA. in the Global Precision Medicine Market
    • 8.9.3 Key Insights about Financial Health of the Company
    • 8.9.4 SWOT Analysis
  • 8.10 Bristol-Myers Squibb Company
    • 8.10.1 Company Overview
    • 8.10.2 Role of Bristol-Myers Squibb Company in the Global Precision Medicine Market
    • 8.10.3 Key Insights about Financial Health of the Company
    • 8.10.4 SWOT Analysis
  • 8.11 Canon Inc.
    • 8.11.1 Company Overview
    • 8.11.2 Role of Canon Inc. in the Global Precision Medicine Market
    • 8.11.3 Key Insights about Financial Health of the Company
    • 8.11.4 SWOT Analysis
  • 8.12 CETICS Healthcare Technologies GmbH
    • 8.12.1 Company Overview
    • 8.12.2 Role CETICS Healthcare Technologies GmbHin the Global Precision Medicine Market
    • 8.12.3 Figure SWOT Analysis
  • 8.13 Danaher Corporation
    • 8.13.1 Company Overview
    • 8.13.2 Role of Danaher Corporation in the Global Precision Medicine Market
    • 8.13.3 Key Insights about Financial Health of the Company
    • 8.13.4 SWOT Analysis
  • 8.14 Eli Lilly and Company Limited
    • 8.14.1 Company Overview
    • 8.14.2 Role of Eli Lilly and Company Limited in the Global Precision Medicine Market
    • 8.14.3 Key Insights about Financial Health of the Company
    • 8.14.4 SWOT Analysis
  • 8.15 Epic Sciences, Inc.
    • 8.15.1 Company Overview
    • 8.15.2 Role Epic Sciences, Inc. in the Global Precision Medicine Market
    • 8.15.3 SWOT Analysis
  • 8.16 F. Hoffmann-La Roche AG
    • 8.16.1 Company Overview
    • 8.16.2 Role of F.Hoffman-LA Roche AG in the Global Precision Medicine Market
    • 8.16.3 Key Insights about Financial Health of the Company
    • 8.16.4 SWOT Analysis
  • 8.17 GE Corporation
    • 8.17.1 Company Overview
    • 8.17.2 Role of GE Corporation in the Global Precision Medicine Market
    • 8.17.3 Key Insights about Financial Health of the Company
    • 8.17.4 SWOT Analysis
  • 8.18 Gilead Sciences, Inc.
    • 8.18.1 Company Overview
    • 8.18.2 Role of Gilead Sciences, Inc. in the Global Precision Medicine Market
    • 8.18.3 Key Insights about Financial Health of the Company
    • 8.18.4 SWOT Analysis
  • 8.19 GlaxoSmithKline Plc
    • 8.19.1 Company Overview
    • 8.19.2 Role of GlaxoSmithKline Plc in the Global Precision Medicine Market
    • 8.19.3 Key Insights about Financial Health of the Company
    • 8.19.4 SWOT Analysis
  • 8.20 IBM Corporation
    • 8.20.1 Company Overview
    • 8.20.2 Role of IBM Corporation in the Global Precision Medicine Market
    • 8.20.3 Key Insights about Financial Health of the Company
    • 8.20.4 SWOT Analysis
  • 8.21 Illumina, Inc.
    • 8.21.1 Company Overview
    • 8.21.2 Role of Illumina, Inc. in the Global Precision Medicine Market
    • 8.21.3 Key Insights about Financial Health of the Company
    • 8.21.4 SWOT Analysis
  • 8.22 Intomics A/S
    • 8.22.1 Company Overview
    • 8.22.2 Role Intomics A/S in the Global Precision Medicine Market
    • 8.22.3 SWOT Analysis
  • 8.23 Johnson & Johnson
    • 8.23.1 Company Overview
    • 8.23.2 Role of Johnson and Johnson in the Global Precision Medicine Market
    • 8.23.3 Key Insights about Financial Health of the Company
    • 8.23.4 SWOT Analysis
  • 8.24 Konica Minolta, Inc.
    • 8.24.1 Company Overview
    • 8.24.2 Role of Konica Minolta, Inc. in the Global Precision Medicine Market
    • 8.24.3 Key Insights about Financial Health of the Company
    • 8.24.4 SWOT Analysis
  • 8.25 Laboratory Corporation of America
    • 8.25.1 Company Overview
    • 8.25.2 Role of Lab Corporation of America in the Global Precision Medicine Market
    • 8.25.3 Key Insights about Financial Health of the Company
    • 8.25.4 SWOT Analysis
  • 8.26 MDxHealth, Inc.
    • 8.26.1 Company Overview
    • 8.26.2 Role of MDx Health, Inc. in the Global Precision Medicine Market
    • 8.26.3 Key Insights about Financial Health of the Company
    • 8.26.4 SWOT Analysis
  • 8.27 Menarini Silicon Biosystems, Inc.
    • 8.27.1 Company Overview
    • 8.27.2 Role Menarini Silicon Biosystems, Inc. in the Global Precision Medicine Market
    • 8.27.3 SWOT Analysis
  • 8.28 Merck & Co., Inc.
    • 8.28.1 Company Overview
    • 8.28.2 Role of Merck & Co., Inc. in the Global Precision Medicine Market
    • 8.28.3 Key Insights about Financial Health of the Company
    • 8.28.4 SWOT Analysis
  • 8.29 Myriad Genetics, Inc.
    • 8.29.1 Company Overview
    • 8.29.2 Role of Myriad Genetics, Inc. in the Global Precision Medicine Market
    • 8.29.3 Key Insights about Financial Health of the Company
    • 8.29.4 SWOT Analysis
  • 8.30 Novartis AG.
    • 8.30.1 Company Overview
    • 8.30.2 Role of Novartis AG in the Global Precision Medicine Market
    • 8.30.3 Key Insights about Financial Health of the Company
    • 8.30.4 SWOT Analysis
  • 8.31 Oracle Corporation.
    • 8.31.1 Company Overview
    • 8.31.2 Role of Oracle Corporation in the Global Precision Medicine Market
    • 8.31.3 Key Insights about Financial Health of the Company
    • 8.31.4 SWOT Analysis
  • 8.32 Pacific Biosciences of California, Inc.
    • 8.32.1 Company Overview
    • 8.32.2 Role of Pacific Biosciences of California, Inc. in the Global Precision Medicine Market
    • 8.32.3 Key Insights about Financial Health of the Company
    • 8.32.4 SWOT Analysis
  • 8.33 Partek, Inc.
    • 8.33.1 Company Overview
    • 8.33.2 Role Partek, Inc. in the Global Precision Medicine Market
    • 8.33.3 SWOT Analysis
  • 8.34 Pfizer, Inc.
    • 8.34.1 Company Overview
    • 8.34.2 Role of Pfizer, Inc. in the Global Precision Medicine Market
    • 8.34.3 Key Insights about Financial Health of the Company
    • 8.34.4 SWOT Analysis
  • 8.35 QIAGEN N.V
    • 8.35.1 Company Overview
    • 8.35.2 Role of QAIGEN N.V in the Global Precision Medicine Market
    • 8.35.3 Key Insights about Financial Health of the Company
    • 8.35.4 SWOT Analysis
  • 8.36 Quest Diagnostics Inc.
    • 8.36.1 Company Overview
    • 8.36.2 Role of Quest Diagnostics Inc. in the Global Precision Medicine Market
    • 8.36.3 Key Insights about Financial Health of the Company
    • 8.36.4 SWOT Analysis
  • 8.37 Randox Laboratories Ltd.
    • 8.37.1 Company Overview
    • 8.37.2 Role of Randox Laboratories Ltd. in the Global Precision Medicine Market
    • 8.37.3 SWOT Analysis
  • 8.38 Sanofi SA
    • 8.38.1 Company Overview
    • 8.38.2 Role of Sanofi SA in the Global Precision Medicine Market
    • 8.38.3 Key Insights about Financial Health of the Company
    • 8.38.4 SWOT Analysis
  • 8.39 Sysmex Corporation
    • 8.39.1 Company Overview
    • 8.39.2 Role of Sysmex Corporation in the Global Precision Medicine Market
    • 8.39.3 Key Insights about Financial Health of the Company
    • 8.39.4 SWOT Analysis
  • 8.40 Teva Pharmaceuticals Industries Ltd.
    • 8.40.1 Company Overview
    • 8.40.2 Role of Teva Pharmaceuticals Industries Ltd. in the Global Precision Medicine Market
    • 8.40.3 Key Insights about Financial Health of the Company
    • 8.40.4 SWOT Analysis
  • 8.41 Thermo Fisher Scientific, Inc.
    • 8.41.1 Company Overview
    • 8.41.2 Role of Thermo Fisher Scientific Inc. in the Global Precision Medicine Market
    • 8.41.3 Key Insights about Financial Health of the Company
    • 8.41.4 SWOT Analysis
  • 8.42 TrovaGene, Inc.
    • 8.42.1 Company Overview
    • 8.42.2 Role of TrovaGene, Inc. in the Global Precision Medicine Market
    • 8.42.3 SWOT Analysis

9 Report Scope and Methodology

  • 9.1 Scope of the Report
  • 9.2 Research Methodology
    • 9.2.1 Primary Research
    • 9.2.2 Secondary Research
    • 9.2.3 Key Data Points from Primary Resources
    • 9.2.4 Key Data Points from Secondary Sources
    • 9.2.5 Data Triangulation

10 List of Annexures

  • 10.1 Recent Key Developments and Strategies
  • 10.2 Product Mapping
  • 10.3 Patent Analysis
  • 10.4 Funding Scenario
  • 10.5 List of Precision Medicine Drugs
  • 10.6 Patent Landscape and Regulatory Bodies
  • 10.7 Cancer Incidence Datasheet
  • 10.8 List of Approved Products
  • 10.9 Competitive Mapping
  • 10.10 PM Initiatives
  • 10.11 List of Universities
  • 10.12 List of Prominent Center of Excellence (CoE)
  • 10.13 Data on Partnerships by Academics, CoE and Industry
  • 10.14 Precision Medicine Drugs Pipeline Analysis
Back to Top